Open AccessEARLY PRESCRIPTION OF PLATELET P2Y12 RECEPTOR INHIBITORS TO PATIENTS WITH ACUTE CORONARY SYNDROME: A BENEFIT OR A HARM?
Author(s) -
Р. М. Шахнович
Publication year - 2018
Publication title -
aterotromboz
Language(s) - English
Resource type - Journals
eISSN - 2658-5952
pISSN - 2307-1109
DOI - 10.21518/2307-1109-2018-2-76-86
Subject(s) - p2y12 , clopidogrel , acute coronary syndrome , aspirin , medicine , medical prescription , ticagrelor , coronary angiography , randomized controlled trial , cardiology , harm , clinical trial , intensive care medicine , myocardial infarction , pharmacology , psychology , social psychology
Double antiplatelet therapy, which includes aspirin and platelet P2Y12 receptor inhibitors (hereinafter P2Y12 inhibitor) is the main component of treatment and secondary prevention after ACS. In recent years, the issue of determining whether it is expedient for P2Y12 inhibitors to be early prescribed to patients with ACS – prior to coronary angiography, when coronary anatomy is unknown – has been widely debated. The review provides comprehensive up-to-date information on this topic based on data from randomized trials, registers, and official clinical guidelines.